Eli Lilly Financials

Eli Lilly and Co

LLYNYSE

Trade with Public

$1160.08

0.080.01%

近くで: Sep 2, 5:00 PM EST

$1161.47

1.390.12%

時間外: 6:04 PM EST

M&A: Merida Biosciences, Inc. announced it will be acquired by Eli Lilly (LLY) on Monday, August 31, 2026 for $2.9B paid in cash

概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

Eli Lilly Financials

Eli Lilly (LLY) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Dow Hits New All-Time High: Investor Sentiment Improves, Fear Index In ‘Greed’ Zone

The CNN Money Fear and Greed index showed improvement in market sentiment on Wednesday, while Dow Jones surged to a record high driven by strong earnings.

Avi Kapoor

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

Eli Lilly (LLY) beat Q2 earnings expectations & raised 2026 guidance as Mounjaro and Zepbound drove $22.97B in revenue. Read more.

Vandana Singh

CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal

CVS Health beats Q2 earnings expectations and hikes FY26 guidance, but shares fall on profit-taking. Get the full financial breakdown.

Vandana Singh

Stock Market Today: S&P 500, Dow Futures Gain After Scott Bessent Signals Strait of Hormuz Deal With Iran in Sight— AMD, SpaceX, SanDisk in Focus (UPDATED)

Dow and S&P 500 indices hit new all-time highs, Treasury Sec. Bessent says Iran deal may reopen Strait of Hormuz.

Benzinga Neuro

Eli Lilly Narrows FY2026 Adj EPS Guidance from $35.50-$37.00 to $35.50-$36.50 vs $34.20 Est; Raises FY2026 Sales Guidance from $82.000B-$85.000B to $85.000B-$87.000B vs $85.446B Est

Eli Lilly (NYSE:LLY) narrows FY2026 Adj EPS guidance from $35.50-$37.00 to $35.50-$35.60 vs $34.20 analyst estimate. Raises FY2026 sales outlook from $82.000 billion-$85.000 billion to $85.000 billion-$87.000 billion vs

Benzinga News-desk

PRO
Eli Lilly Q2 Adj. EPS $8.38 Beats $6.01 Estimate, Sales $22.974B Beat $20.725B Estimate

Eli Lilly (NYSE:LLY) reported quarterly earnings of $8.38 per share which beat the analyst consensus estimate of $6.01 by 39.43 percent. This is a 32.81 percent increase over earnings of $6.31 per share from the same

Benzinga Newsdesk

Eli Lilly and Co

Eli Lilly Financials

Earnings & Guidance News

Dow Hits New All-Time High: Investor Sentiment Improves, Fear Index In ‘Greed’ Zone

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal

Stock Market Today: S&P 500, Dow Futures Gain After Scott Bessent Signals Strait of Hormuz Deal With Iran in Sight— AMD, SpaceX, SanDisk in Focus (UPDATED)

Eli Lilly Narrows FY2026 Adj EPS Guidance from $35.50-$37.00 to $35.50-$36.50 vs $34.20 Est; Raises FY2026 Sales Guidance from $82.000B-$85.000B to $85.000B-$87.000B vs $85.446B Est

PRO
Eli Lilly Q2 Adj. EPS $8.38 Beats $6.01 Estimate, Sales $22.974B Beat $20.725B Estimate

ニュース

パートナーシップ

ベンジンガ・グローバル

Benzinga

Benzinga

Benzinga

Eli Lilly and Co

Eli Lilly Financials

Earnings & Guidance News

Dow Hits New All-Time High: Investor Sentiment Improves, Fear Index In ‘Greed’ Zone

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal

Stock Market Today: S&P 500, Dow Futures Gain After Scott Bessent Signals Strait of Hormuz Deal With Iran in Sight— AMD, SpaceX, SanDisk in Focus (UPDATED)

Eli Lilly Narrows FY2026 Adj EPS Guidance from $35.50-$37.00 to $35.50-$36.50 vs $34.20 Est; Raises FY2026 Sales Guidance from $82.000B-$85.000B to $85.000B-$87.000B vs $85.446B Est

PROEli Lilly Q2 Adj. EPS $8.38 Beats $6.01 Estimate, Sales $22.974B Beat $20.725B Estimate

Benzinga

ニュース

パートナーシップ

ベンジンガ・グローバル

PRO
Eli Lilly Q2 Adj. EPS $8.38 Beats $6.01 Estimate, Sales $22.974B Beat $20.725B Estimate